Dr Shibani Nicum
Telephone:
Location:
- University College Hospital
GMC/GDC number:
4285049
Professional background
Dr Shibani Nicum is a Consultant Medical Oncologist and an Associate Professor of Medical Oncology at University College Hospital London, specialising in the treatment of women with gynaecological cancers. She trained at The Royal Marsden Hospital and was a consultant in Oxford from 2009, prior to moving to London in 2021.
Shibani is also the Chair of the National Cancer Research Institute (NCRI) Gynaecological Group and Lead for Gynaecological Trials at the Cancer Research UK and UCL Cancer Trials Centre. Her research interests are in BRCA-mutated cancers and the development of novel therapies in order to improve and personalise patient care. She has led a number of CR UK funded studies, including the international ICON9, OCTOVA and 6MP BRCA trials.
In addition to her oncological practice, she is leading the development of services and research to improve the care of women with treatment induced menopause following a cancer diagnosis and for those who have a hereditary risk of developing cancer. She is a member of the All Parliamentary Party Group led by the Menopause and Ovarian Cancer Select Committees, and the British Gynaecological Cancer Society Menopause Guidelines Consensus Group.
Specialties
Research interests
Novel therapies; clinical trials; personalised treatment options; BRCA-related cancers; cancer treatment-induced menopause.
Selected publications:
Nicum S, Blagden SP. PARPs: Enhancing Diversity in Clinical Trials. All for One and One for All? Clin Cancer Res. 2022 Jun 1;28(11):2201-2203.
Morgan RD, Ferreras C, Peset I, Avizienyte E, Renehan AG, Edmondson RJ, Murphy AD, Nicum S, Van Brussel T, Clamp AR, Lambrechts D, Zhou C, Jayson GC. c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. BMC Med. 2022 Feb 11;20(1):59. doi: 10.1186/s12916-022-02270-y.
Taylor A, Sundar SS, Bowen R, Clayton R, Coleridge S, Fotopoulou C, Ghaem-Maghami S, Ledermann J, Manchanda R, Maxwell H, Michael A, Miles T, Nicum S, Nordin A, Ramsay B, Rundle S, Williams S, Wood NJ, Yiannakis D, Morrison J. British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic. Int J Gynecol Cancer. 2022 Jan;32(1):9-14. doi: 10.1136/ijgc-2021-002942. Epub 2021 Nov 18. PMID: 34795019.
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Vergote I, and participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research. Lancet Oncol. 2022 Aug;23(8):e374-e384. doi: 10.1016/S1470-2045(22)00139-5. Erratum in: Lancet Oncol. 2022 Sep;23(9):e404. PMID: 35901833.
Blagden SP, Nicum S. A source of hope for platinum-resistant ovarian cancer? Lancet. 2021 Jan 23;397(10271):254-256. doi: 10.1016/S0140-6736(21)00128-8. PMID: 33485431.
Mansouri A, McGregor N, Dunn R, Dobbie S, Holmes J, Collins L, Nicum S. Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol. BMJ Open. 2021 Jan 15;11(1):e041463. doi: 10.1136/bmjopen-2020-041463. PMID: 33452192; PMCID: PMC7813404.
Elyashiv O, Ledermann J, Parmar G, Farrelly L, Counsell N, Feeney A, El-Khouly F, Macdonald I, Neto A, Arthur-Darkwa E, Burnett E, Jayson GC, Mileshkin L, Gourley C, Nicum S. ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. Int J Gynecol Cancer. 2021 Jan;31(1):134-138. doi: 10.1136/ijgc-2020-002073. Epub 2020 Oct 23. PMID: 33097567.
A Kazmi F, Nicum S, Roux RL, Spiers L, Gnanaranjan C, Sukumaran A, Gabra H, Ghazaly E, McCracken NW, Harrison DJ, Blagden SP. Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer.Clin Cancer Res. 2021 Jun 1;27(11):3028-3038. doi: 10.1158/1078-0432.CCR-20-4403. Epub 2021 Mar 19. PMID: 33741651.
Frangou E, Bertelli G, Love S, Mackean MJ, Glasspool RM, Fotopoulou C, Cook A, Nicum S, Lord R, Ferguson M, Roux RL, Martinez M, Butcher C, Hulbert-Williams N, Howells L, Blagden SP. OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer. Gynecol Oncol. 2021 Aug;162(2):431-439. doi: 10.1016/j.ygyno.2021.05.024. Epub 2021 May 29. PMID: 34059348.
Artibani M, Masuda K, Hu Z, Rauher PC, Mallett G, Wietek N, Morotti M, Chong K, KaramiNejadRanjbar M, Zois CE, Dhar S, El-Sahhar S, Campo L, Blagden SP, Damato S, Pathiraja PN, Nicum S, Gleeson F, Laios A, Alsaadi A, Santana Gonzalez L, Motohara T, Albukhari A, Lu Z, Bast RC Jr, Harris AL, Ejsing CS, Klemm RW, Yau C, Sauka-Spengler T, Ahmed AA. Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells. JCI Insight. 2021 Jun 8;6(11):e147929. doi: 10.1172/jci.insight.147929. PMID: 33945502; PMCID: PMC8262282.
Sundar S, Manchanda R, Gourley C, George A, Wallace A, Balega J, Williams S, Wallis Y, Edmondson R, Nicum S, Frost J, Attygalle A, Fotopoulou C, Bowen R, Bell D, Gajjar K, Ramsay B, Wood NJ, Ghaem-Maghami S, Miles T, Ganesan R. British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom. Int J Gynecol Cancer. 2021 Feb;31(2):272-278. doi: 10.1136/ijgc-2020-002112. Epub 2021 Jan 19. Erratum in: Int J Gynecol Cancer. 2021 Dec;31(12):1619. PMID: 33468564.
V Strauss, S Kopijasz, C Gourley, M Hall, A Montes, J Abraham, A R Clamp, R Kennedy, S Banerjee, L Folkes, M Stratford, and S Nicum. Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours. British Journal of Cancer; Br J Cancer 2020; 122(4):483–49
Gynecol Oncol. Hall MR, Dehbi HM, Banerjee S, Lord R, Clamp A, Ledermann JA, Nicum S, Lilleywhite R, Bowen R, Michael A, Feeney A, Glasspool R, Hackshaw A, Rustin G. A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer. 2020 Dec;159(3):692-698. doi: 10.1016/j.ygyno.2020.09.048. Epub 2020 Oct 16. PMID: 33077258.
R L. Coleman, G F. Fleming, M F. Brady, E M. Swisher, K D. Steffensen, M Friedlander, A Okamoto, KN. Moore,NE Ben-Baruch, T L. Werner, NG. Cloven, A Oaknin, P A. DiSilvestro, M A. Morgan, J Nam, C A. Leath III, S Nicum, A R. Hagemann, R D. Littell, D Cella, S Baron-Hay, J Garcia-Donas, M Mizuno, K Bell-McGuinn, D M. Sullivan, A. Bach, S Bhattacharya, C K. Ratajczak, PJ. Ansell, M H. Dinh, C Aghajanian, M A. Bookman. Veliparib with Front-Line Chemotherapy and as Maintenance in Ovarian Cancer.N Engl J Med 2019; 381:2403-2415
N Colombo, C Sessa, J Ledermann, ESMO- ESGO Ovarian Cancer Consensus Conference Working Group et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology 2019; 30(5):672-705